Quick reference guide to apixaban

Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and conseque...

Full description

Saved in:
Bibliographic Details
Published in:Vascular health and risk management 2017-01, Vol.13, p.263-267
Main Authors: Hurst, Katherine Victoria, O'Callaghan, John Matthew, Handa, Ashok
Format: Article
Language:English
Subjects:
Administration, Oral
Anticoagulants
Apixaban
Blood Coagulation - drug effects
Cardiac arrhythmia
Cardiovascular disease
Clinical medicine
Clinical trials
Cytochrome
Diabetes
Disease prevention
Drug dosages
Drug therapy
Embolisms
Factor Xa Inhibitors - administration & dosage
Factor Xa Inhibitors - adverse effects
Factor Xa Inhibitors - pharmacokinetics
Glycoproteins
Health risk assessment
Heart failure
Hemorrhage - chemically induced
Humans
Hypertension
Knee
Licenses
Patient outcomes
Patients
Pyrazoles - administration & dosage
Pyrazoles - adverse effects
Pyrazoles - pharmacokinetics
Pyridones - administration & dosage
Pyridones - adverse effects
Pyridones - pharmacokinetics
Review
Risk Factors
Stroke
Stroke - blood
Stroke - epidemiology
Stroke - prevention & control
stroke management
Surgeons
Thromboembolism
Thrombosis
Treatment Outcome
Veins & arteries
venous thromboembolism
Venous Thromboembolism - blood
Venous Thromboembolism - epidemiology
Venous Thromboembolism - prevention & control
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Direct oral anticoagulants (DOACs) are being increasingly used in the clinical setting for patients at risk of venous thromboembolism (VTE) and/or stroke. These medications offer valued benefits for long-term use, including a fast onset of anticoagulation, fixed anticoagulation profile (and consequent prescription of specified doses) and no requirement for routine monitoring. Apixaban is a selective factor Xa inhibitor, approved for use in the prevention of stroke in patients with nonvalvular atrial fibrillation and in the prevention and treatment of acute VTE. Like many of the DOACs, it has a fast onset of action and works to deliver predictable coagulation results. Multiple randomized controlled trials including ARISTOTLE and AMPLIFY have shown apixaban to be noninferior to vitamin K antagonists in the prevention of stroke and VTE, with a good safety profile. This article aims to review the use of apixaban for the prevention and treatment of thromboembolic disease, highlighting the key study results that have led to its current licensing and use.
ISSN:1178-2048
1176-6344
1178-2048
DOI:10.2147/VHRM.S121944